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Summary
N8, a new recombinant factor VIII (rFVIII) compound developed for the treatment of haemophilia
A, is produced in Chinese hamster ovary (CHO) cells and formulated without human- or animal-
derived materials. The aim of the present study was to compare the pharmacokinetics (PK) and the
procoagulant effect, measured by ex vivo whole blood clot formation, of N8 and a commercial
rFVIII in a cross-over study in haemophilia A dogs. N8 and Advate® (100 IU kg−1) were
administered intravenously to three haemophilia A dogs. Blood was sampled between 0 and 120 h
postdose and FVIII:C analysed. PK parameters maximum plasma concentration, area under the
curve, half-life (t½), clearance, mean residence time (MRT) and volume of distribution and
incremental recovery were calculated. Whole blood clotting time (WBCT) and
thromboelastography (TEG®) were used to determine the haemostatic potential. No adverse
reactions were observed with N8 or Advate®. N8 and Advate® exhibited similar PK parameters,
with t½ 7.7–11 h and MRT 11–14 h. Both rFVIII compounds corrected the prolonged WBCT (>48
min) to the range of normal dogs (8–12 min), i.e. N8 to 7.5–10.5 min and Advate® to 7.5–11.5
min. N8 and Advate® also normalized the whole blood clot formation according to TEG®. The
native whole blood clotting assays (WBCT, TEG®) appeared to be more sensitive to low
concentrations of FVIII than assays in citrated plasma samples. In conclusion, comparison of N8
and Advate® in haemophilia A dogs revealed similar safety, similar PK and similar effects in
whole blood clot formation assays.
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Haemophilia A is the most common severe inherited bleeding disorder, with an estimated
incidence of only one in every 5000 live male births [1]. It results from a deficiency or
defect in coagulation Factor VIII (FVIII), leading to impaired thrombin generation on
activated platelets [2]. The bleeding tendency of haemophilia A correlates well with the
level of FVIII activity in plasma and without treatment, patients with severe haemophilia A
(FVIII plasma levels <1% of normal) experience frequent spontaneous bleeding episodes
[3]. For an optimal outcome, prophylactic treatment is important. In young boys,
prophylaxis with recombinant FVIII (rFVIII) concentrate decreases the frequency of
haemorrhages and prevents joint damage compared with episodic treatment at the time of
haemarthrosis [4]. To improve haemophilia care, treatment for all patients must be available.
However, there is disparity in the availability of treatment worldwide, with more than 75%
of patients with haemophilia receiving either inadequate or no treatment [5–7].
N8 is a new rFVIII compound developed for the treatment of haemophilia A [8]. N8 is
produced in Chinese hamster ovary (CHO) cells and formulated without the use of animal-
or human-derived materials, thereby eliminating the risk of transmission of infections. N8
comprises an 88-kDa heavy chain (A1-a1-A2-a2) followed by a 21 amino acid sequence of
the natural B domain (amino acids 741–750 fused with 1638–1648) and a 79-kDa light
chain containing the a3-A3-C1-C2 domains [8]. Characterization of the N8 protein has
confirmed its primary structure, including the presence of all six known tyrosine sulphations
of FVIII such as tyrosine sulphation of Y1680 required for binding to von Willebrand factor
(VWF) [8]. Detailed functional in vitro characterization has shown that N8 is fully active in
a variety of assays measuring FVIII activity, with no functional difference with the
comparator licensed recombinant or plasma-derived FVIII products, Advate® (Baxter,
Vienna, Austria) and Haemate® (CSL Behring, Marburg, Germany) [9]. Binding of N8 to
VWF was confirmed, suggesting normal clearance in the presence of VWF. A global Phase
III clinical trial programme is assessing the efficacy and safety of N8 in patients with severe
haemophilia A. A Phase I pharmacokinetic study in patients with severe haemophilia
showed bioequivalence of N8 to Advate(R) [10] and a global Phase III clinical trial
programme is currently assessing the efficacy and safety of N8 in patients with severe
haemophilia A.
Dogs with congenital haemophilia A and B are used extensively to evaluate the
pharmacokinetics (PK) and efficacy of human coagulation factors [11–13]. There are close
similarities in gene and protein structure between human and canine FVIII [14]. In addition,
several studies have shown similarities between haemophilia dogs and human patients with
regard to severe bleeding phenotype, as well as the PK of haemostatic proteins [13]. Thus,
haemophilia dog models are established as highly predictive of the efficacy and safety of
replacement therapy in humans [13].
The aim of this study was to determine the PK and the ex vivo effect on whole blood clot
formation of N8 after intravenous (i.v.) administration to haemophilia A dogs. For
comparison, Advate® [15] was used in a cross-over design. The ability of N8 and Advate®
to induce clot formation in haemophiliaAdogs was evaluated by whole blood clotting time
(WBCT) and thromboelastography (TEG®) assays. As it was not feasible to evaluate in vivo
efficacy in the dogs at multiple time points, the whole blood clot formation parameters were
used as surrogate markers for pharmacodynamic (PD) effects.
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The study was conducted using three haemophilia A dogs [one male (K18) and two female
(M37 and M51)] from the haemophilia dog colony at the Francis Owen Blood Research
Laboratory University of North Carolina, Chapel Hill, NC, USA [13]. The dogs had not
previously been dosed with human FVIII. The protocol was approved by the Institutional
Animal Care and Use Committee at the University of North Carolina as well as by Novo
Nordisk’s animal ethical committee.
Study design
N8 and Advate® (100 IU kg−1) were administered to the haemophiliaAdogs intravenously.
In a cross-over design, dogs K18 andM51received Advate® first followed byN8 and dog
M37 received N8 first followed by Advate®. A washout period of 48 h between the two
infusions was designed to limit the risk of interference from the previous infusion. The dogs
were infused with a bolus dose in a cephalic vein via a 22G Butterfly at 0.7 mL min−1,
alternating between the left and right cephalic vein.
Sample collection
Blood was sampled at selected time points between 0 and 120 h by transcutaneous puncture
of a cephalic vein using a 21G or comparable Butterfly. Samples were drawn immediately
prior to each infusion, and 5, 15 and 30 min, 1, 2, 3, 4, 6, 8, 12, 24 and 32 h after each
infusion. Samples were also drawn on day 3 (48, 56 h), day 4 (72, 80 h) and day 5 (96, 120
h) after the second infusion. Blood was stabilized in 0.12 M sodium citrate (10:1),
centrifuged and the plasma analysed for FVIII:C in a chromogenic assay [16]. Whole blood
was analysed in WBCT and TEG® assays (see below). Samples were also taken
immediately before each infusion and 72 h after the second infusion for analysis of the
development of FVIII antibodies (Bethesda assay) [17].
Ex vivo whole blood clot formation (pharmacodynamic analysis)
The haemostatic process was recorded by a TEG® coagulation analyser (Haemoscope;
Haemoscope Corporation, Chicago, IL, USA) and was initiated with kaolin (lot 1106-0605)
as indicated by the manufacturer. Blood was analysed within 2 min of collection. TEG®
recordings proceeded for 90 min and the TEG® reaction time (R-time), maximum clot
firmness (MA) and angle were determined. WBCT was determined as described [18,19].
Pharmacokinetic analysis
The PK profiles of N8 and Advate® were evaluated by non-compartment analysis (NCA)
using PK software WinNonLin on the basis of FVIII:C data. PK parameters analysed were
maximum plasma concentration (Cmax), area under the activity vs. time curve (AUC)
extrapolated to infinity, half-life on the terminal part of the curve (t½), clearance (Cl), mean
residence time (MRT), volume of distribution at steady state (Vss) and incremental recovery
[Cmax/dose, in units (U dL−1)/(U kg−1)] according to ISTH guidelines 2001.
Pharmacokinetic parameters were compared using a paired two-sample Student’s t-test
(Microsoft Excel 2003).
Haematology
Blood samples were analysed for platelet counts, white cell counts and haematocrit at 0 h
(before the first infusion), at 30 min, 1, 4 and 24 h after each infusion, and 72 h and 96 h
after the second infusion.
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Haemophilia A dogs at baseline
Baseline characteristics of the three haemophilia A dogs are shown in Table 1. The
haemophilia A dogs displayed prolonged WBCT and R-time by TEG®. If a clot was
initiated at all, the clot development (angle) was very low. Consequently, the MA did not
reach the normal range within the time of the analysis. Haematology parameters at baseline
were within or close to the normal range (Table 1).
Pharmacokinetic analysis
N8 and Advate® showed similar FVIII:C profiles (Fig. 1). Plasma FVIII:C increased at the
first sampling time point after the i.v. injection, then declined, exhibiting a biphasic
disappearance. The estimated PK parameters for the individual dogs as well as the mean
values [with 95% confidence intervals (CI)] are shown in Table 2. N8 and Advate®
exhibited similar values for all PK parameters assessed, with no statistically significant
differences between the three dogs (P > 0.05).
Surrogate pharmacodynamic assays
The prolonged WBCT at baseline normalized at the first time point (5 min) after injection of
N8 or Advate®, then slowly increased (Fig. 2). N8 and Advate® both corrected WBCT to
the range of normal dogs, i.e. N8 to 7.5–10.5 min and Advate® to 7.5–11.5 min (Table 3).
Examples of TEG® traces for dog M51 before and after Advate® and N8 administration are
shown in Fig. 3B, C. Both compounds normalized the TEG® traces at the first sampling
time (5 min). The clot time (R-time), clot development (angle) and maximal clot firmness
(MA) 5 min after N8 or Advate® infusion (Table 3) were close to those reported in normal
dogs (Table 1). In the three dogs, mean R-time stayed markedly shortened for up to 12 h;
near-baseline R-times were reached by 72 h (Fig. 4a). These changes in R-time were similar
to the changes in WBCT (Fig. 2). Also the angle (Fig. 4b) increased markedly by the first
time point after infusion and then remained virtually unchanged for up to 12 h, after which a
decrease was observed until the values returned to baseline by 72 h. The sustained
normalization of the parameters obtained in the native whole blood clotting assays (WBCT,
TEG®) up to 12 h is in contrast to the more rapid decrease of FVIII:C measurements in
citrated plasma samples suggesting that the native whole blood clotting assays are more
sensitive to the presence of low concentrations of FVIII than FVIII:C analyses.
Safety
There were no safety concerns during the study and both compounds were well tolerated. No
significant changes occurred in platelet counts or white cell counts following administration
of N8 or Advate® (data not shown). There was a slight decrease in the platelet count (to 149
× 103 mm−3) and haematocrit (to 34.2%) following the second infusion in dog K18,
probably because of the multiple sampling as the values returned to normal within 48 h.
Inhibitors to FVIII were not detected at any time points in the three dogs.
Discussion and conclusion
This cross-over study in haemophilia A dogs demonstrated that N8 and Advate® had similar
safety, seen as an absence of adverse reactions. Furthermore, the data suggested similar
efficacy for N8 and Advate®, as shown by PK based on FVIII:C measurements and
surrogate PD parameters WBCT and TEG® profiles. In this study, N8 and Advate®
exhibited a t½ of 7.7–11 h and MRT of 11–14 h. The data are consistent with previously
published FVIII data in dogs. In a previous cross-over study of haemophilia A dogs,
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infusion of either ReFacto® (Genetics Institute, Andover, MA, USA) or Octonativ-M7®
(Pharmacia, Stockholm, Sweden) at 125 IU kg−1 quickly corrected FVIII:C, WBCT and
activated partial thromboplastin time (aPTT) [12]. The values for t½ (11.7 and 10.8 h
respectively) and MRT (15.9 and 14.3 h respectively) were in the same range as in this
study.
Safety assessment in this study showed no adverse reactions with N8 or Advate®. There
were no persistent changes in platelet counts, haematocrit or white blood cell count.
Furthermore, inhibitors to FVIII were not detected during the study.
It is well established that haemophilia A dogs are predictive of the human condition [13].
Therefore, the PK and surrogate PD data in this study suggest that a comparable haemostatic
effect of N8 and Advate® can be expected in patients with haemophilia A. This was
confirmed in a very recently reported multinational, open-label, sequential trial of patients
with severe haemophilia A, in which the PK profiles of N8 and Advate® were comparable,
bioequivalence was demonstrated and there were no safety concerns [10]. The t½ of N8 in
humans was reported to 10.83 ± 4.95 h, which is similar to the t½ in dogs reported here. A
limitation of the present study is the small number of animals used. Furthermore, the dog
model cannot predict immunogenicity in humans. Despite these limitations, the similar PK
findings between haemophilia A dogs and patients support the suitability of the dog model.
In this study, both N8 and Advate® normalized impaired clot formation. The two FVIII
compounds had a similar immediate effect and a similar duration of effect. Interestingly, the
WBCT and TEG® parameters were normalized for ~12 h whereas a gradual decrease in
FVIII:C was observed. The FVIII:C assay was sensitive to ~1% of normal FVIII levels (0.01
IU mL−1), which was reached after 48 h, while the WBCT and R-time from the TEG®
analysis did not return to baseline until 96–108 h and 60–72 h respectively. The data suggest
that the WBCT and TEG® R-times are sensitive to very low levels of FVIII not measurable
by FVIII:C.
In conclusion, based on the absence of adverse reactions and the PK and surrogate PD
profiles, N8 has comparable safety and ex vivo efficacy to Advate® in haemophilia A dogs.
These data predict that N8 will be as effective as Advate® in managing human haemophilia
A.
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Mean (±SD) profile of FVIII:C vs. time on (a) a linear scale and (b) a log scale for three
haemophilia A dogs following i.v. administration of N8 and Advate® (100 IU kg−1).
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Mean profile of WBCT vs. time for three haemophilia A dogs following i.v. administration
of N8 and Advate® (100 IU kg−1). The shaded area indicates the normal range.
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Thromboelastography (TEG®) traces of kaolin-initiated coagulation in native whole blood
from a haemophilia A dog receiving Advate® and N8. (A) shows a TEG® trace from a
normal dog (solid line) and a haemophilia A dog (dotted line) with indications of the TEG®
parameters. R-time (R) is the latency time from clot initiation until an amplitude of 2 mm is
reached. MA is the maximum amplitude, i.e. the maximum strength of the clot. Angle (a) is
measured between R and the point where the amplitude reaches 20 mm and reflects the clot
development. (B) and (C) are the TEG® traces for dog M51 before and following i.v.
administration of Advate® and N8 (100 IU kg−1).
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Mean profile of TEG® (a) clot formation (R-time) and (b) clot development (angle) vs. time
for three haemophilia A dogs following i.v. administration of N8 and Advate® (100 IU
kg−1).
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Table 1
Baseline characteristics of haemophilia A dogs.
K18 M37 M51 Normal range
Sex Male Female Female –
Weight (kg) 19.8 14.9 16.4 –
Treatment (dose 100 IU kg−1) Advate® then N8 N8 then Advate® Advate®then N8 –
FVIII:C (IU mL−1) <0.02 <0.02 <0.02 0.66–1.2 [20]
WBCT (min) 38.5 28.0 49.0 8–12
TEG®
 R-time (min) >60 23 >60 6–12
 Angle (degree) 0.4 2.3 ND ~68
 MA (mm) 2.1 3.6 ND ~65
Haematology
 Platelet count (103 mm−3) 278 223 192 200–500
 WBC (103 mm−3) 15.2 8.2 8.3 6.0–17.0
 Haematocrit (%) 41.4 51.7 49.2 37–55
 Haemoglobin (g dL−1) 13.8 17.0 16.5 12.0–18.0
ND, not detectable; WBCT, whole blood clotting time; TEG®, thromboelastography; R-time, reaction time; MA, maximum amplitude.
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Table 3
Haemostatic response of haemophilia A dogs to infusions of N8 and Advate®. Values measured at first
sampling point, t = 5 min.
Assay N8 Advate®
WBCT (min) 7.5–10.5 7.5–11.5
TEG®
 R-time (min) 9.2–12.9 9.7–12.2
 Angle (degree) 57.8–62.6 55.5–58.4
 MA (mm) 56.9–67.8 62.0–63.4
WBCT, whole blood clotting time; TEG®, thromboelastography; R-time, reaction time; MA, maximum amplitude.
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